Global Cancer Immunotherapies Markets, 2017 - Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation

News provided by

Oct 12, 2017, 13:30 ET

DUBLIN, October 12, 2017 /PRNewswire/ --

The "Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets" drug pipelines has been added to Research and Markets' offering.

The report "Frontier Pharma: Cancer Immunotherapies - First-in-Class Pipeline Dominated by Immunomodulators and PD-1 Like Targets" is a comprehensive study of disease pathogenesis, diagnosis, prognosis and the treatment options available.

Specifically, this report:

Visualize the composition of the cancer immunotherapies market in terms of dominant molecule types and targets, highlighting what the current unmet needs are and how they can be addressed.
Analyze the cancer immunotherapies pipeline and stratify by stage of development, molecule type and molecular target.
Assess the therapeutic potential of first-in-class targets. Using a proprietary molecular target matrix tailored directly towards cancer immunotherapies, first-in-class products have been assessed and ranked according to clinical potential.
Helps to identify commercial opportunities in the cancer immunotherapies deals landscape by analyzing trends in licensing and co-development deals, and producing a list of first-in-class therapies with no prior involvement in licensing or co-development deals.

Scope

The 3,100 products in active development, of which 989 are first-in-class and therefore act on completely novel targets, far exceed the scope of the current market. How will pipeline innovation affect the future cancer immunotherapies market?
There are 322 distinct first-in-class molecular targets currently being studied. Which of these hold the greatest potential to improve future disease treatment with regard to their molecular target?
Multiple types of cancer immunotherapies exist. Which of these are the most promising, and how does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?
A significant number of first-in-class products have been identified with some prior involvement in deals. How do deal frequency and value compare between target families and molecule types, and which first-in-class programs have not yet been involved in a licensing or co-development deal?

Key Topics Covered:

1 Table of Contents

2 Executive Summary
2.1 A Large Therapy Area with Varying Unmet Needs across Indications
2.2 A Large Pipeline with a High Degree of First-in-Class Innovation

3 The Case for Innovation in the Oncology Market
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Report Guidance

4 Clinical and Commercial Landscape
4.1 Therapy Area Overview
4.1.1 Epidemiology
4.1.2 Etiology
4.1.3 Pathophysiology
4.1.4 Diagnosis
4.1.5 Prognosis and Disease Staging
4.2 Treatment Options
4.2.1 Surgery
4.2.2 Radiation Therapy
4.2.3 Chemotherapy
4.2.4 Hormonal Therapies
4.2.5 Targeted Therapies
4.2.6 Immunotherapies
4.3 Overview of Marketed Products within Cancer Immunotherapy
4.4 Current Unmet Needs across the Oncology Markets

5 Assessment of Pipeline Product Innovation
5.1 Cancer Immunotherapies Pipeline by Phase, Molecule Type and Molecular Target
5.2 Comparative Distribution of Programs between the Oncology Market and Pipeline by Therapeutic Target Family
5.3 First-in-Class Pipeline Programs
5.3.1 First-in-Class Cancer Immunotherapy Products by Phase, Molecule Type and Molecular Target

6 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
6.1 The Complexity of Signaling Networks in Oncology
6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration
6.3 First-in-Class Target Matrix Assessment

7 First-in-Class Target Assessment
7.1 Pipeline Programs that Target Low-Affinity Immunoglobulin Gamma Fc Region Receptor IIIA
7.2 Pipeline Programs that Target Programmed Death 1 Ligand-2
7.3 Pipeline Programs that Target OX-2 Membrane Glycoprotein/CD200
7.4 Pipeline Programs that Target Killer-Cell Immunoglobulin-Like Receptors
7.5 Pipeline Programs that Target Toll-Like Receptors
7.6 Pipeline Programs that Target Inducible T-Cell Costimulator
7.7 Pipeline Programs that Target Membrane Cofactor Protein
7.8 Pipeline Programs that Target NKG2-A/NKG2-B Type II Integral Membrane Protein
7.9 Pipeline Programs that Target Stimulator of Interferon Genes Protein
7.10 Conclusion

8 Deals and Strategic Consolidations
8.1 Licensing Deals
8.2 Co-development Deals

9 Appendix
9.1 Abbreviations
9.2 References
9.3 Research Methodology
9.3.1 Data Integrity
9.3.2 Innovative and Meaningful Analytical Technique and Frameworks
9.3.3 Evidence-based Analysis and Insight
9.4 Secondary Research
9.4.1 Market Analysis
9.4.2 Pipeline Analysis
9.4.3 First-in-Class Matrix Assessment
9.4.4 First-in-Class Target Profiles
9.4.5 Licensing and Co-Development Deals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/3fcmmt/frontier_pharma

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets